Endocrine Abstracts

Background: Resistin was originally proposed in animal models as a link between obesity and insulin resistance, but later studies in humans have shown a divergent role. Yet, resistin seems to be involved in the development of atherosclerosis in humans by promoting the formation of foam cells; further, its expression is induced by oxidized low-density lipoproteins (LDL) in human macrophages.Methods: We assessed the relationships between resistin and marke...

ObjectiveFat depot in the tongue that represents 25–30% of the total tongue mass is largely unaddressed. It correlates with body mass index. The response to weight reduction induced by different anti-obesity modalities may vary between body fat compartments. Semaglutide, a long acting GLP-1 receptor agonist (GLP-1 RA), has the potential to reduce body mass with at least 2 to 3 times greater weight reduction than other studied GLP-1 RAs. This is the ...

Introduction: Liraglutide exerts cardio-protective effects beyond of those on glucose metabolism, affecting several cardio-metabolic parameters, such as subclinical atherosclerosis. However, it is not known if those effects differ in the long-term between pre-elderly and elderly subjects with type-2 diabetes (T2DM).Methods: We included 135 subjects with T2DM divided in 2 groups: i) 71 pre-elderly subjects (46 men and 25 women, 55±7 years), and ii) 6...

Background: There is evidence that rosiglitazone may increase cardiovascular risk and, on this basis, this agent has been recently advised for treatment of type-2 diabetes. Yet, its effects on fasting and postprandial atherogenic dyslipidemia are still not fully elucidated.Methods: In an open-label study rosiglitazone (4 mg/day for 12 weeks) was added on top of a maximum of two oral antidiabetic drugs to 18 patients with adequately controlled type-2 diab...